Holdings
BlackRock Health Sciences Opportunities Portfolio
As of May 29, 2026, BlackRock Health Sciences Opportunities Portfolio reported 127 positions worth US$5.82B. Largest: Eli Lilly And Company, Johnson & Johnson and Unitedhealth Group Incorporated. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly And Company | 657K | US$726M | −47,692 | May 29, 2026 |
| Johnson & Johnson | 2.3M | US$518M | −389K | May 29, 2026 |
| Unitedhealth Group Incorporated | 947K | US$360M | +270K | May 29, 2026 |
| Merck & Company, Inc. | 2.46M | US$292M | +585K | May 29, 2026 |
| Gilead Sciences, Inc. | 1.84M | US$248M | +105K | May 29, 2026 |
| Abbvie Inc. | 1.07M | US$233M | −89,681 | May 29, 2026 |
| Amgen Inc. | 590K | US$199M | +2,045 | May 29, 2026 |
| Thermo Fisher Scientific Inc | 362K | US$178M | +77,051 | May 29, 2026 |
| Vertex Pharmaceuticals Incorporated | 362K | US$162M | +88,589 | May 29, 2026 |
| Pfizer, Inc. | 5.9M | US$154M | +4.71M | May 29, 2026 |